No matches
Pulmonology

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
Philippe Gevaert
MD, PhD
Philippe Gevaert

Related resources

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

expert video
Compounded Burden of Co-existing Type 2 Airway Diseases

Compounded Burden of Co-existing Type 2 Airway Diseases

expert video
Adult Asthma Interactive Patient Cases

Adult Asthma Interactive Patient Cases

interactivity
IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

expert video
How does a decrease in smell affect sleep disturbance? Is there any direct relation?

How does a decrease in smell affect sleep disturbance? Is there any direct relation?

expert video
Loss of Smell is a Key Symptom of CRSwNP

Loss of Smell is a Key Symptom of CRSwNP

interactivity
ERS-ISIAN 2025 | Disease Control in CRSwNP

ERS-ISIAN 2025 | Disease Control in CRSwNP

expert video
CRSwNP: A Chronic Type 2 Inflammatory Disease

CRSwNP: A Chronic Type 2 Inflammatory Disease

expert video
IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

expert video
Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video
Understanding IL-33: A Key Factor in COPD Pathogenesis

Understanding IL-33: A Key Factor in COPD Pathogenesis

interactivity
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

expert video
Partnering With Patients: Scores That Matter in CRSwNP

Partnering With Patients: Scores That Matter in CRSwNP

interactivity
IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

expert video
When is the right time to consider a biologic in patients with CRSwNP?

When is the right time to consider a biologic in patients with CRSwNP?

expert video
Blood Eosinophils: A Biomarker in COPD

Blood Eosinophils: A Biomarker in COPD

Infographic
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

expert video
Mucus Plugging as a Potential Target in Asthma Management

Mucus Plugging as a Potential Target in Asthma Management

expert video
Connecting Type 2 Inflammation to CRSwNP

Connecting Type 2 Inflammation to CRSwNP

expert video
Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

interactivity
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

expert video
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

expert video
ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

expert video
CRSwNP Triathlon: An Interactive Learning Experience

CRSwNP Triathlon: An Interactive Learning Experience

interactivity
Multifaceted Role of IL-13 in Airway Remodeling

Multifaceted Role of IL-13 in Airway Remodeling

expert video
GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

interactivity
Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Infographic
Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

expert video
Dr. Giorgio Canonica Regarding Multidisciplinary Approach

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

expert video
ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

expert video
Pediatric Asthma Trajectory and Clinical Remission

Pediatric Asthma Trajectory and Clinical Remission

expert video
CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

interactivity
How Can Poor Lung Function Impact Asthma Burden in Adult Patients?

How Can Poor Lung Function Impact Asthma Burden in Adult Patients?

videoanimation
How often do you suggest to assess sense of smell?

How often do you suggest to assess sense of smell?

expert video
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

expert video
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up

expert video
Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

expert video
2025 ADVENT Forum | Potential for Disease Modification in the Airway

2025 ADVENT Forum | Potential for Disease Modification in the Airway

expert video
ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

Podcast
How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?

How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?

videoanimation
What proportion of patients can achieve control in CRSwNP?

What proportion of patients can achieve control in CRSwNP?

expert video
Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

expert video
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video

Learning objectives

  • To discuss the impact of co-existing type 2 inflammatory diseases on patient burden and management approaches
Tags
quality of lifebiologicsexpert insightssymposiumtype 2 inflammationasthmaCRSwNP
MAT-GLB-2505227 - 1.0 - 09/2025

About this expert

Allergy/Immunology
Rhinology

Philippe Gevaert

MD, PhD

Professor of Rhinology and Allergy in the Department of Otorhinolaryngology | Ghent University, Belgium

See author’s profile
Philippe Gevaert

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BahrainChange country/region